Biondvax Pharmaceuticals Ltd - ADR

NASDAQ:BVXV   3:59:53 PM EDT
1.27
-0.13 (-9.29%)
Products, Regulatory

Biondvax Pharmaceuticals Ltd Signs Definitive Agreements For Development And Commercialization Of Innovative Nanosized Covid-19 Antibody Therapy

Published: 12/22/2021 12:28 GMT
Biondvax Pharmaceuticals Ltd - ADR (BVXV) - Biondvax Pharmaceuticals Ltd -.
Biondvax Signs Definitive Agreements for Development and Commercialization of Innovative Nanosized Covid-19 Antibody Therapy With Max Planck Institute of Biophysical Chemistry and University Medical Center GÖttingen, Germany.
Biondvax Pharmaceuticals Ltd - Initial Human Clinical Trials Results Expected in 2023.
Biondvax Pharmaceuticals Ltd - Anticipates Conducting Covid-19 Nanoab Preclinical Studies in 2022.
Biondvax Pharmaceuticals Ltd- Broader Collaboration for Development of Additional Nanoabs Expected to Be Signed in January 2022.